George S L, Aur R J, Mauer A M, Simone J V
N Engl J Med. 1979 Feb 8;300(6):269-73. doi: 10.1056/NEJM197902083000601.
We examined the results of stopping therapy in children with acute lymphocytic leukemia. Of 639 patients in eight consecutive "total therapy" studies, 278 (44 per cent) had all treatment stopped, usually after 2 1/2 years of complete remission. About one fifth (55 of 278) of this group have relapsed, mainly in the bone marrow. The relapse rate for the first year off therapy was higher than that for the next three years (0.16 vs. 0.04, P less than 0.01). The life-table estimates of the four-year relapse rates were 0.24 for all patients and 0.22 for patients receiving adequate central-nervous system prophylaxis. Boys had a higher relapse rate than girls (0.33 vs. 0.15 P less than 0.01). None of the 79 patients who remained in complete remission for at least four years off therapy have yet relapsed. Acute lymphocytic leukemia appears curable in over one third of all newly diagnosed patients who receive treatment for approximately 2 1/2 years.
我们研究了急性淋巴细胞白血病患儿停止治疗的结果。在连续八项“全疗程治疗”研究的639例患者中,278例(44%)停止了所有治疗,通常是在完全缓解2年半后。该组中约五分之一(278例中的55例)复发,主要是骨髓复发。停止治疗第一年的复发率高于接下来三年(0.16对0.04,P<0.01)。所有患者四年复发率的生命表估计值为0.24,接受充分中枢神经系统预防的患者为0.22。男孩的复发率高于女孩(0.33对0.15,P<0.01)。79例停止治疗后至少四年保持完全缓解的患者均未复发。在所有新诊断并接受约2年半治疗的患者中,超过三分之一的急性淋巴细胞白血病似乎可以治愈。